Conquering Diseases

Study of a New Investigational Drug for Treatment of Recurrent Clostridium Difficile Infection


Seeking adults 18 years or older who have had 3 or more infections with Clostridium difficile (CDI) in the past 9 months including at the time they join the study. Half of the participants will be given the study drug and the other half will be given a placebo (fake pill). You cannot choose and will not be told which group you are in while in the study.


Patients who are eligible to join the study will take 4 pills daily for 3 days in a row. Visits are by phone and in-person. Side effects and benefits will be noted by questionnaires, symptom diary records and through tests like stool and urine samples, blood draws and physical exam by the study doctor. During the study you may decide, if eligible, to join a follow on study.

What we're hoping for

To learn if a new medicine is safe and helpful in the treatment of recurrent Clostridium difficile infection as compared with no treatment (placebo).

Additional Information Identifier: NCT03183128

 Principal Investigator

JeanMarie  Houghton, MD, PhD

University of Massachusetts Medical School

 Study Contact

The Gastrointestinal Research  Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655